603392 万泰生物
已收盘 11-13 15:00:00
资讯
新帖
简况
万泰生物（603392）11月11日主力资金净卖出443.64万元
证券之星 · 11-12
万泰生物（603392）11月11日主力资金净卖出443.64万元
万泰生物（603392）11月9日主力资金净卖出592.30万元
证券之星 · 11-10
万泰生物（603392）11月9日主力资金净卖出592.30万元
股市必读：万泰生物（603392）11月4日董秘有最新回复
证券之星 · 11-05
股市必读：万泰生物（603392）11月4日董秘有最新回复
万泰生物：九价HPV疫苗国际注册正积极有序推进
证券之星 · 11-04
万泰生物：九价HPV疫苗国际注册正积极有序推进
万泰生物：股份回购属于重大事项，需综合考量公司现金流、资本开支、经营规划并履行严格法定决策程序
证券之星 · 11-04
万泰生物：股份回购属于重大事项，需综合考量公司现金流、资本开支、经营规划并履行严格法定决策程序
万泰生物（603392）2026年三季报简析：增收不增利，公司应收账款体量较大
证券之星 · 10-28
万泰生物（603392）2026年三季报简析：增收不增利，公司应收账款体量较大
万泰生物（603392）10月27日主力资金净卖出4330.03万元
证券之星 · 10-28
万泰生物（603392）10月27日主力资金净卖出4330.03万元
10月27日万泰生物跌9.97%，华夏国证疫苗与生物科技指数发起A基金重仓该股
证券之星 · 10-27
10月27日万泰生物跌9.97%，华夏国证疫苗与生物科技指数发起A基金重仓该股
九价疫苗放量难止亏，万泰生物前三季度净亏损扩大至2.31亿元
东方财富网 · 10-27
九价疫苗放量难止亏，万泰生物前三季度净亏损扩大至2.31亿元
图解万泰生物三季报：第三季度单季净利润同比下降248.68%
证券之星 · 10-27
图解万泰生物三季报：第三季度单季净利润同比下降248.68%
万泰生物最新公告：前三季度净亏损2.31亿元
证券之星 · 10-26
万泰生物最新公告：前三季度净亏损2.31亿元
万泰生物（603392）10月15日主力资金净买入174.64万元
证券之星 · 10-16
万泰生物（603392）10月15日主力资金净买入174.64万元
万泰生物（603392）10月13日主力资金净卖出944.05万元
证券之星 · 10-14
万泰生物（603392）10月13日主力资金净卖出944.05万元
股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》
证券之星 · 10-14
股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》
万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计
证券之星 · 10-13
万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计
万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险
证券之星 · 10-12
万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险
万泰生物：公司海外业务主要以美元作为计价结算币种
证券之星 · 10-12
万泰生物：公司海外业务主要以美元作为计价结算币种
万泰生物：公司后续会加强投资者沟通
证券之星 · 10-12
万泰生物：公司后续会加强投资者沟通
万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一
证券之星 · 10-12
万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一
万泰生物：公司有梅毒快速检测试剂盒相关产品
证券之星 · 10-12
万泰生物：公司有梅毒快速检测试剂盒相关产品
加载更多
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":22.85,"timestamp":1794553200000,"preClose":23.51,"halted":0,"volume":4691450,"delay":0,"changeRate":-0.0281,"floatShares":1264000000,"shares":1264000000,"eps":-0.3604,"marketStatus":"已收盘","change":-0.66,"latestTime":"11-13 15:00:00","open":23.42,"high":23.48,"low":22.83,"amount":108000000,"amplitude":0.0276,"askPrice":22.87,"askSize":35,"bidPrice":22.85,"bidSize":301,"shortable":0,"etf":0,"ttmEps":-0.3604,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":23.51,"symbolType":"stock","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":25.86,"lowLimit":21.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1264392804,"isCdr":false,"pbRate":2.48,"roa":"--","roe":"--","epsLYR":-0.31,"committee":0.892131,"marketValue":28891000000,"turnoverRate":0.0037,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-16。","floatMarketCap":28891000000},"requestUrl":"/m/hq/s/603392","defaultTab":"news","newsList":[{"id":"2682536392","title":"万泰生物（603392）11月11日主力资金净卖出443.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682536392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682536392?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:28","pubTimestamp":1794443307,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月11日收盘，万泰生物报收于23.95元，下跌1.84%，换手率0.26%，成交量3.34万手，成交额8018.25万元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入475.88万元，融资偿还467.41万元，融资净买入8.46万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200006519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","LU1981816686.USD","BK0239","09633","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682356391","title":"万泰生物（603392）11月9日主力资金净卖出592.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682356391","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682356391?lang=zh_cn&edition=full","pubTime":"2026-11-10 09:38","pubTimestamp":1794274691,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月9日收盘，万泰生物报收于24.38元，下跌2.09%，换手率0.28%，成交量3.59万手，成交额8826.84万元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入423.48万元，融资偿还738.22万元，融资净偿还314.74万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000010820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1589","LU1981816686.USD","BK0239","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681645460","title":"股市必读：万泰生物（603392）11月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2681645460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681645460?lang=zh_cn&edition=full","pubTime":"2026-11-05 03:32","pubTimestamp":1793820733,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘，万泰生物报收于24.61元，上涨0.41%，换手率0.47%，成交量5.96万手，成交额1.45亿元。公司严格按照增值税相关法律法规执行计税调整，相关业务已适用13%税率。公司九价HPV疫苗自国内上市后，在土耳其正式提交申请到今年最终取得证书，前后历时较长。请广大投资者以公司法定披露公告为准。股价受多重市场因素影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500004816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","LU1981816686.USD","603392","09633","BK1200","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680039101","title":"万泰生物：九价HPV疫苗国际注册正积极有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2680039101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680039101?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:33","pubTimestamp":1793784794,"startTime":"0","endTime":"0","summary":"公司九价HPV疫苗国际注册正积极有序推进，今年以来取得多项进展：2026年5月正式完成向WHO提交PQ认证申请，并于6月30日获得WHO正式受理；欧洲市场方面，向欧洲药品管理局递交的科学建议申请已通过资料验证并正式启动审评程序；此外，九价HPV疫苗已于2026年8月在泰国获批上市。公司第三代HPV疫苗临床前研究按计划有序进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","159646","BK0239","BK1589","LU1981816686.USD","09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680236039","title":"万泰生物：股份回购属于重大事项，需综合考量公司现金流、资本开支、经营规划并履行严格法定决策程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2680236039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680236039?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:33","pubTimestamp":1793784793,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：目前股价马上近一年跌幅44.7%，马上接近“近一年跌幅50%”,请问公司董事会是否做好了回购的预案及回购资金的前期准备工作。万泰生物回复：您好！股价受多重市场因素影响。股份回购属于重大事项，需综合考量公司现金流、资本开支、经营规划并履行严格法定决策程序，若后续筹划回购，将依规履行审议程序和信息披露义务。公司将继续扎实做好主营业务，以经营基本面回报股东。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","159399","603392","BK1200","09633","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678467154","title":"万泰生物（603392）2026年三季报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2678467154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678467154?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:13","pubTimestamp":1793189604,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期万泰生物发布2026年三季报。本报告期万泰生物公司应收账款体量较大，当期应收账款占最新年报营业总收入比达83.52%。本次财报公布的各项数据指标表现一般。持有万泰生物最多的基金为华夏国证疫苗与生物科技指数发起A，目前规模为0.66亿元，最新净值0.5809，较上一交易日下跌3.01%，近一年下跌19.02%。本文数据来源于万泰生物2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800046617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","BK1589","BK0239","603392","LU1981816686.USD","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678480697","title":"万泰生物（603392）10月27日主力资金净卖出4330.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678480697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678480697?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:38","pubTimestamp":1793147933,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月27日收盘，万泰生物报收于23.22元，下跌9.97%，换手率1.29%，成交量16.29万手，成交额3.89亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入1922.73万元，融资偿还8633.41万元，融资净偿还6710.68万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800014055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","LU1981816686.USD","BK0239","09633","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678121407","title":"10月27日万泰生物跌9.97%，华夏国证疫苗与生物科技指数发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678121407","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678121407?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:41","pubTimestamp":1793090488,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日万泰生物跌9.97%创60日新低，收盘报23.22元，换手率1.29%，成交量16.29万手，成交额3.89亿元。重仓万泰生物的公募基金请见下表：根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华夏基金的华夏国证疫苗与生物科技指数发起A。华夏国证疫苗与生物科技指数发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700030972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","HBImain","BK1589","LU1981816686.USD","BK0239","603392","159646","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678612456","title":"九价疫苗放量难止亏，万泰生物前三季度净亏损扩大至2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678612456","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678612456?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:27","pubTimestamp":1793089672,"startTime":"0","endTime":"0","summary":"九价HPV疫苗放量带来营收增长，却没能让万泰生物走出亏损。10月26日晚间，万泰生物发布2026年三季报，公司前三季度实现营收16.23亿元，同比增长8.29%；净亏损2.31亿元，较上年同期的亏损1.73亿元进一步扩大。不过，受益于九价HPV疫苗收入提升，公司整体毛利得到改善，扣非后净亏损较上年同期收窄至2.86亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610273909878390.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610273909878390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["09633","603392","BK1200","159646","BK0239","LU1981816686.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678118597","title":"图解万泰生物三季报：第三季度单季净利润同比下降248.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678118597","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678118597?lang=zh_cn&edition=full","pubTime":"2026-10-27 01:20","pubTimestamp":1793035226,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物2026年三季报显示，前三季度公司主营收入16.23亿元，同比上升8.29%；归母净利润-2.31亿元，同比下降33.07%；扣非净利润-2.86亿元，同比上升6.99%；其中2026年第三季度，公司单季度主营收入5.74亿元，同比下降12.33%；单季度归母净利润-1.02亿元，同比下降248.68%；单季度扣非净利润-1.17亿元，同比下降80.33%；负债率12.97%，投资收益4468.55万元，财务费用1136.9万元，毛利率63.4%。财报数据概要请见下图:本文数据来源于万泰生物2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700002853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678615541","title":"万泰生物最新公告：前三季度净亏损2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678615541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678615541?lang=zh_cn&edition=full","pubTime":"2026-10-26 18:02","pubTimestamp":1793008959,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，第三季度营业收入为5.74亿元，同比下降12.33%；归属于上市公司股东的净利润为-1.02亿元。前三季度营业收入为16.23亿元，同比增长8.29%；归属于上市公司股东的净利润为-2.31亿元。注：公司Q3净利润亏损1.02亿，Q2净利润-0.85亿，据此计算，Q3净利润环比持续亏损。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600024699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","LU1981816686.USD","BK1200","603392","BK1589","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675595245","title":"万泰生物（603392）10月15日主力资金净买入174.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675595245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675595245?lang=zh_cn&edition=full","pubTime":"2026-10-16 08:16","pubTimestamp":1792109779,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，万泰生物报收于25.3元，上涨0.4%，换手率0.44%，成交量5.5万手，成交额1.39亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入598.63万元，融资偿还1338.39万元，融资净偿还739.76万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600007147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392","BK1200","BK0239","LU1981816686.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675396861","title":"万泰生物（603392）10月13日主力资金净卖出944.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675396861","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675396861?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:30","pubTimestamp":1791937854,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，万泰生物报收于25.74元，下跌2.17%，换手率0.42%，成交量5.3万手，成交额1.37亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入852.95万元，融资偿还1526.37万元，融资净偿还673.42万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1981816686.USD","09633","BK1200","603392","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675369921","title":"股市必读：万泰生物新发布《万泰生物关于公司冻干重组呼吸道合胞病毒疫苗（CHO细胞）获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369921","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675369921?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:38","pubTimestamp":1791913090,"startTime":"0","endTime":"0","summary":"截至2026年10月13日收盘，万泰生物报收于25.74元，下跌2.17%，换手率0.42%，成交量5.3万手，成交额1.37亿元。公司公告汇总：万泰生物全资子公司冻干重组呼吸道合胞病毒疫苗获国家药监局临床试验批准，拟用于预防60岁及以上人群RSV所致下呼吸道疾病。公司高度重视人工智能技术与疫苗研发的深度融合。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392","LU1981816686.USD","BK0239","159646","BK1589","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675339464","title":"万泰生物：依托平台集群叠加大数据与AI工具实现新型疫苗抗原自主设计","url":"https://stock-news.laohu8.com/highlight/detail?id=2675339464","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675339464?lang=zh_cn&edition=full","pubTime":"2026-10-13 15:34","pubTimestamp":1791876888,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问邱总：请介绍一下，公司为生物疫苗人工智能究竟做了哪些具体性实质性的工作？万泰生物回复：您好！公司高度重视人工智能技术与疫苗研发的深度融合。在研发环节，依托公司搭建的覆盖疫苗研发全周期的抗原设计与临床前评价平台集群，叠加大数据与AI工具，实现新型疫苗抗原自主设计、专利壁垒突破和多维度临床前有效性验证，从源头提升创新疫苗管线临床申报转化率和商业化落地可行性。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300020593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","09633","BK0239","BK1200","BK1589","LU1981816686.USD","159739","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674387302","title":"万泰生物：鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2674387302","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674387302?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796690,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物10月12日在投资者关系平台上答复投资者关心的问题。还有戊肝疫苗，5亿的研发成本，卖出不到100万剂。鼻喷新冠、二价 HPV 存货计提是外部市场环境变化、供需格局变动带来的经营风险；水痘疫苗项目仍在推进；戊肝疫苗作为全球首创产品，市场培育周期较长。公司重大项目均履行相应审议决策流程，管理层对公司经营承担勤勉尽责责任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","LU1981816686.USD","BK0239","09633","BK1589","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873073","title":"万泰生物：公司海外业务主要以美元作为计价结算币种","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873073?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796688,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问：公司与泰国印尼等国家的收费是以人民币、美元还是当地货币结算，结算周期一般多长时间？谢谢。万泰生物回复：您好！公司海外业务主要以美元作为计价结算币种，结算周期根据不同业务模式有所区分。公司高度重视海外回款风险，通过投保出口信用保险、前置客户资质尽调、审慎选择合作方、合理约定付款条款、动态跟踪回款进度等方式保障海外收款安全。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","LU1981816686.USD","BK0239","BK1589","09633","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674287302","title":"万泰生物：公司后续会加强投资者沟通","url":"https://stock-news.laohu8.com/highlight/detail?id=2674287302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674287302?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796688,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物10月12日在投资者关系平台上答复投资者关心的问题。在遵守信息披露监管要求的前提下，公司后续会加强投资者沟通。公司管理层将持续深耕主业，扎实做好经营，力争以长期业绩回报投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","09633","BK0239","BK1589","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873046","title":"万泰生物：越南是公司HPV疫苗国际化布局的目标市场之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873046?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:18","pubTimestamp":1791796686,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，与我国接壤的越南，人口大国且经济情况良好，为何至今贵司的HPV疫苗还没有进入该国？ 是在准入方面遇到了困难了吗？万泰生物回复：您好！越南是公司HPV疫苗国际化布局的目标市场之一。但国际上各个国家的药品监管要求不同，准入时间周期也不同。根据越南当地药品监管要求，目前相关注册准入工作正按计划有序推进。公司将严格按照监管要求及时履行信息披露义务。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","159646","09633","FVNmain","BK1589","603392","BK0239","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674873117","title":"万泰生物：公司有梅毒快速检测试剂盒相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2674873117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674873117?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:09","pubTimestamp":1791796152,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，目前有媒体报道了国外某国的梅毒激增，贵公司是否有生产梅毒快速检测试剂盒？目前梅毒快速试剂检测是否会出口？今年1至9月，贵公司的梅毒快速试剂检测盒的销量是否同比增长？谢谢万泰生物回复：您好！公司有梅毒快速检测试剂盒相关产品，该产品可对外出口。公司各类梅毒检测试剂包含化学发光、酶免、胶体金（快速检测）及质控品等多品类，产品出口覆盖亚、欧、非、拉美各大洲 20 多个国家和地区。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200022451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1981816686.USD","BK1589","09633","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794748463301,"stockEarnings":[{"period":"1week","weight":-0.0823},{"period":"1month","weight":-0.0933},{"period":"3month","weight":-0.2409},{"period":"6month","weight":-0.4224},{"period":"1year","weight":-0.5845},{"period":"ytd","weight":-0.4915}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"46972人(较上一季度增加9.43%)","perCapita":"26918股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126439万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}